CHARACTERIZATION OF MUSCARINIC RECEPTORS IN GUINEA-PIG UTERUS

被引:70
作者
DOODS, HN [1 ]
WILLIM, KD [1 ]
BODDEKE, HWGM [1 ]
ENTZEROTH, M [1 ]
机构
[1] SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND
关键词
MUSCARINIC RECEPTOR; SMOOTH MUSCLE; UTERUS; MUSCARINIC M2 RECEPTOR; M4 BINDING SITE;
D O I
10.1016/0014-2999(93)90385-U
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To characterize the muscarinic receptor present in guinea-pig uterus smooth muscle the affinities of a series of 27 muscarinic receptor antagonists for M1 (rat cortex), M2 (rat heart), M3 (rat submandibular gland), m4 (transfected in CHO cells) and muscarinic binding sites in guinea-pig uterus smooth muscle were determined in radioligand binding studies. In addition, functional experiments were performed to assess pK(B) values of the antagonist for muscarinic receptors in guinea-pig atrium and uterus. The results obtained are consistent with the presence Of M2 receptors in the uterus through which the functional contractile response is mediated. Correlation coefficients of 0.98, 0.91 and 0.91 were calculated for the following linear regressions: pK(i) uterus vs. pK(i) M2, pK(B) uterus vs. pK(i) M2 and pK(B) uterus vs. pK(B) atrium. This study also revealed that the compounds dicyclomine, DAU 5884, DAU 6202 as well as AQ-RA 721 could distinguish m4 from M2 sites and are therefore important tools to characterize muscarinic receptor subtypes. In addition, DAU 5884 and DAU 6202 have been identified as highly potent M1 selective antagonists.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 36 条
[1]   CHARACTERIZATION OF MUSCARINIC RECEPTOR SUBTYPES INHIBITING CA2+ CURRENT AND M-CURRENT IN RAT SYMPATHETIC NEURONS [J].
BERNHEIM, L ;
MATHIE, A ;
HILLE, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (20) :9544-9548
[2]   PHARMACOLOGICAL PROPERTIES OF CLONED MUSCARINIC RECEPTORS EXPRESSED IN A9 L CELLS - COMPARISON WITH INVITRO MODELS [J].
BODDEKE, HWGM ;
BUTTINI, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 202 (02) :151-157
[3]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]  
Dahlquist F W, 1978, Methods Enzymol, V48, P270
[6]  
DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257
[7]  
DORJE F, 1990, N-S ARCH PHARMACOL, V342, P284
[8]  
DORJE F, 1991, MOL PHARMACOL, V40, P459
[9]  
DORJE F, 1992, THESIS J WOLFGANG GO
[10]  
EGLEN R M, 1991, British Journal of Pharmacology, V104, p44P